等待开盘 08-10 09:30:00 美东时间
+0.255
+4.47%
William Blair starts Zura Bio (NASDAQ: ZURA) at Outperform, citing tibulizumab's multibillion-dollar potential in autoimmune disease.
07-09 01:24
HC Wainwright & Co. analyst Mitchell Kapoor initiates coverage on Zura Bio (NASDAQ:ZURA) with a Neutral rating and announces Price Target of $5.
2024-09-05 18:59
05:55 PM EDT, 09/03/2024 (MT Newswires) -- Zura Bio (ZURA) filed a shelf registration statement with the US Securities and Exchange Commission Tuesday covering the potential sale of up to $300 million of ordinary shares, preferred shares, debt securities, warrants and units from time to time in one ...
2024-09-04 05:55
Cantor Fitzgerald analyst Josh Schimmer reiterates Zura Bio (NASDAQ:ZURA) with a Overweight.
2024-08-15 20:20